Evidence map›Paper›PMID 34772435›Full record

ArticleOrphanet journal of rare diseases2021

An Integrated clinical pathway for diagnosis, treatment and care of rare diseases: model, operating procedures, and results of the project TRANSLATE-NAMSE funded by the German Federal Joint Committee.

Daniela Choukair, Fabian Hauck, Markus Bettendorf, Heiko Krude, Christoph Klein, Tobias Bäumer, Reinhard Berner, Min Ae Lee-Kirsch, Corinna Grasemann, Peter Burgard and 1 more

Abstract readCase Reports
In one paragraph

Article in Orphanet journal of rare diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Review
  2. [Rare diseases: a concept for a structured diagnostic pathway].Innere Medizin (Heidelberg, Germany) · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Patient passports for rare diseases: results of a pilot study.European journal of human genetics : EJHG · 2026
    Article
  7. Article
  8. Article
  9. Observational
  10. Article
  11. Article
  12. Article
  13. [Healthcare for people with rare diseases: recommendations for successful intersectoral collaboration].Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz · 2023
    Article
  14. Article
  15. Review
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Daniela ChoukairCenter for Child and Adolescent Medicine and Center for Rare Diseases, University Hospital Heidelberg, 69120, Heidelberg, Germany.
Fabian HauckDepartment of Pediatrics, Dr Von Hauner Children's Hospital, University Hospital and Munich Centre for Rare Diseases, LMU Munich, 80337, Munich, Germany.
Markus BettendorfCenter for Child and Adolescent Medicine and Center for Rare Diseases, University Hospital Heidelberg, 69120, Heidelberg, Germany.
Heiko KrudeInstitute for Experimental Pediatric Endocrinology, and Berlin Center for Rare Diseases, Charité - Universitätsmedizin Berlin, 13353, Berlin, Germany.
Christoph KleinDepartment of Pediatrics, Dr Von Hauner Children's Hospital, University Hospital and Munich Centre for Rare Diseases, LMU Munich, 80337, Munich, Germany.
Tobias BäumerInstitute of Systems Motorscience and Center for Rare Diseases, University of Lübeck, 23562, Lübeck, Germany.
Reinhard BernerDepartment of Pediatrics and University Center for Rare Diseases, University Hospital Carl Gustav Carus, Technische Universität Dresden, 01307, Dresden, Germany.
Min Ae Lee-KirschDepartment of Pediatrics and University Center for Rare Diseases, University Hospital Carl Gustav Carus, Technische Universität Dresden, 01307, Dresden, Germany.
Corinna GrasemannDepartment of Pediatrics, St-Josef Hospital Bochum and and Center for Rare Diseases, Ruhr-University Bochum, 44791, Bochum, Germany.
Peter Burgard *Center for Child and Adolescent Medicine and Center for Rare Diseases, University Hospital Heidelberg, 69120, Heidelberg, Germany. peter.burgard@t-online.de.ORCID 0000-0003-0665-8025
Georg F HoffmannCenter for Child and Adolescent Medicine and Center for Rare Diseases, University Hospital Heidelberg, 69120, Heidelberg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDiagnosis, treatment, and care of patients with rare diseases require multidisciplinary cooperation between medical and paramedical specialities and with patients and families. Innovative genetic diagnostics, whole exome and whole genome sequencing (WES, WGS) has enlarged the diagnostic toolkit but also increased the complexity of the endeavour. Structured multidisciplinary clinical pathways (CPW) can guide diagnosis, treatment, and care of patients with rare diseases, link scientific evidence to clinical practice and optimise clinical outcomes whilst maximising clinical efficiency.

resultsIn contrast to the common approach of appending disease-specific CPWs to disease-specific guidelines, we suggest a generic CPW manoeuvring the patient along the way of finding the correct diagnosis by applying the best diagnostic strategy into an appropriate system of treatment and care. Available guidelines can be integrated into the generic CPW in the course of its application. The approach also applies to situations where a diagnosis remains unsolved. The backbone of the generic CPW is a set of multidisciplinary structured case conferences projecting and evaluating diagnostic and/or therapeutic steps, enforcing to integrate best scientific evidence with clinical experience. The generic CPW is stated as a flowchart and a checklist which can be used to record and document parsimoniously the structure, process and results of a patient's pathway, but also as a data model for research. It was applied in a multicentre setting with 587 cases each with a presumptive diagnosis of a rare disease. In 369 cases (62.8%) a diagnosis could be confirmed, and multidisciplinary treatment and/or care was initiated. The median process time from first contact until confirmation of diagnosis by WES was 109 days and much shorter than diagnostic delays reported in the literature. Application of the CPW is illustrated by two case reports.

conclusionsOur model is a tool to change the diagnostic odyssey into an organised and trackable route. It can also be used to inform patients and families about the stages of their individual route, to update health care providers only partially involved or attending specialised treatment and care, like the patient's or family's primary physician, and finally to train novices in the field.

Indexed as

Critical PathwaysRare DiseasesExomeExome SequencingHumansCase managementClinical pathwayDiagnostic odysseyEvidence-based medicineRare diseases

Identifiers

PMID34772435
PMCPMC8588640

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.